"Unfortunately, these numbers do not get rid of my doubts. The clinical trial was able to demonstrate a slowing of disease progression, but it’s still not possible to say if that reaches a level that any [family member or acquaintance] would be able to notice outside of a controlled clinical trial."

The risk of these anti-amyloid drugs is real and high.

If the effect is to prolong suffering, is it really something you'd want?

#Donanemab #ALZ #Amyloid
https://www.science.org/content/blog-post/lilly-s-alzheimer-s-data-donanemab

Yet another anti-#amyloid #drug for #alzheimers #dementia. Press release by company:

✅ positive effect on #cognition
❌ 25% #brain oedema
❌ threefold increase in microbleeds
❌ 2% increase in serious bleeds
⁉️ full paper⁉️

Lilly's Donanemab Significantly Slowed Cognitive and Functional Decline in Phase 3 Study of Early Alzheimer's Disease

https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-significantly-slowed-cognitive-and-functional

RT @SjorsScheres
Great news today! We will soon be advertising a postdoc position to join our work on #cryoEM structures of #amyloid filaments, in particular our efforts to reproduce in the lab filaments with the same structures as observed in disease. 🥳
Happy to be contacted by DM or email.

Nach zwei Anläufen könnte es diesmal was werden mit dem ersten #Amyloid-Antikörper, der die Progression der #Alzheimer-Demenz bremst. Aber die Gretchenfrage bleibt: Wie relevant ist der Effekt?
http://docc.hk/kcyr8m

@wheelersimon as a colleague pointed out - the lack of clinical effectiveness concurrent with inconsistent #amyloid removal could be seen as at least partly positive.